Is Celyad Oncology S.A. (CLYYF) a Buy, Sell, or Hold?
OTC : CLYYF
Celyad Oncology S.A.
$0.2 USD
$0 (0.0%)
- Volume
- 100
- Average Volume
- 1
- Market Capitalization
- $8.95M
- P/E Ratio
- 14.03
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.53
- Year Low
- $0.15
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.92
Company Overview
OTC
Michel E. J. Lussier
Biotechnology
Healthcare
CLYYF
17
BE
USD
Liquidity Metrics
0.00
1.92
1.92
0.94
0.00
Sales & Valuation
$20991
616.01
4.91
-1.87
-0.17
Profitability
$0.0179
$829.69K
3833.33%
3833.33%
-242.11%
18.73%
P/E Metrics
14.03
0.10
0.10
Analyst Price Target & Rating
4/5
4 Analysts
%
Financial Health Scores
-125.19
1/9
$1.68M
$4.3M
$1.86M
-$12.87M
Key Metrics (TTM)
$11.23M
534.68
-1.60
1.92
-242.11%
-289.60%
6.72%
-53.34%
$0.16
13863 days
Company Executives
| Name | Title |
|---|---|
| Michel E. J. Lussier | Co-Founder & Non-Executive Director |
| Philippe Dechamps | Corporate Secretary |
| An Phan | Head of Legal |
| David Georges | Vice President of Finance & Administration |
| Sara Zelkovic | Communications & Investor Relations Director |
Poll Results
No votes yet today — be the first to share your view!
About Celyad Oncology S.A. (OTC:CLYYF) Stock
Celyad Oncology SA is a clinical-stage biopharmaceutical entity dedicated to the discovery and advancement of chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. Its prominent clinical programs include CYAD-101, an allogeneic CAR-T candidate in a Phase 1b trial for metastatic colorectal cancer. Another significant asset is CYAD-211, an allogeneic CAR-T therapy based on short hairpin RNA (shRNA), currently undergoing Phase 1 evaluation for relapsed/refractory multiple myeloma. Additionally, CYAD-02, an autologous CAR-T candidate, is in Phase 1 trials for individuals with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. Within its preclinical pipeline, the company is developing CYAD-203, a non-gene-edited allogeneic CAR-T candidate engineered ... to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for potential application in solid tumors. Celyad Oncology has established key collaborations, including a licensing agreement with Novartis International AG concerning U.S. patents for allogeneic CAR-T cells. It also maintains a research and development partnership, alongside licensing agreements, with Horizon Discovery Group plc to utilize their shRNA technology in creating a novel non-gene-edited allogeneic platform. Founded in 2004 as Celyad SA, the company rebranded to Celyad Oncology SA in June 2020 and is headquartered in Mont-Saint-Guibert, Belgium.
Frequently Asked Questions
-
What is the current Celyad Oncology S.A. (CLYYF) stock price?
-
Celyad Oncology S.A.(OTC:CLYYF) stock price is $0.2 in the last trading session. During the trading session, CLYYF stock reached the peak price of $0.53 while $0.15 was the lowest point it dropped to. The percentage change in CLYYF stock occurred in the recent session was 0.0% while the dollar amount for the price change in CLYYF stock was $0.
-
CLYYF's industry and sector of operation?
-
The OTC listed CLYYF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CLYYF?
-
Michel E. J. Lussier | Co-Founder & Non-Executive Director
Philippe Dechamps | Corporate Secretary
An Phan | Head of Legal
David Georges | Vice President of Finance & Administration
Sara Zelkovic | Communications & Investor Relations Director -
How many employees does CLYYF have?
-
Number of CLYYF employees currently stands at 17. CLYYF operates from Axis Business Park, Mont-Saint-Guibert, WA 1435, BE.
-
Link for CLYYF official website?
-
Official Website of CLYYF is: https://www.celyad.com
-
How do I contact CLYYF?
-
CLYYF could be contacted at phone #32 1 039 41 00 and can also be accessed through its website. CLYYF operates from Axis Business Park, Mont-Saint-Guibert, WA 1435, BE.
-
How many shares of CLYYF are traded daily?
-
The average number of CLYYF shares traded daily for last 3 months was 1.
-
What is the market cap of CLYYF currently?
-
The market value of CLYYF currently stands at $8.95M with its latest stock price at $0.2